Whitehawk Therapeutics (NASDAQ:WHWK) versus IMV (OTCMKTS:IMVIQ) Financial Review

IMV (OTCMKTS:IMVIQ) and Whitehawk Therapeutics (NASDAQ:WHWK) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, analyst recommendations, dividends and profitability.

Valuation and Earnings

This table compares IMV and Whitehawk Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IMV	$330,000.00	0.00	-$37.99 million	($4.59)	N/A
Whitehawk Therapeutics	$25.98 million	5.99	-$63.69 million	$0.14	23.57

IMV has higher earnings, but lower revenue than Whitehawk Therapeutics. IMV is trading at a lower price-to-earnings ratio than Whitehawk Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares IMV and Whitehawk Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
IMV	N/A	N/A	N/A
Whitehawk Therapeutics	N/A	-68.32%	-63.21%

Analyst Recommendations

This is a summary of current ratings and recommmendations for IMV and Whitehawk Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IMV	0	0	0	0	0.00
Whitehawk Therapeutics	1	1	2	0	2.25

Whitehawk Therapeutics has a consensus target price of $6.50, indicating a potential upside of 96.97%. Given Whitehawk Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Whitehawk Therapeutics is more favorable than IMV.

Volatility & Risk

IMV has a beta of 0.9, suggesting that its share price is 10% less volatile than the S&P 500. Comparatively, Whitehawk Therapeutics has a beta of 0.59, suggesting that its share price is 41% less volatile than the S&P 500.

Insider and Institutional Ownership

52.1% of Whitehawk Therapeutics shares are owned by institutional investors. 0.3% of IMV shares are owned by insiders. Comparatively, 49.9% of Whitehawk Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Whitehawk Therapeutics beats IMV on 7 of the 11 factors compared between the two stocks.

About IMV

IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and MSI-H solid tumors, as well as in Phase I clinical trial for breast cancer. It also develops DPX-SurMAGE that is in Phase I clinical trial for bladder cancer; and DPX-COVID-19 and DPX-RSV for infectious diseases. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.

About Whitehawk Therapeutics

Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.